Savara Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Savara Inc. on February 3, 2020, covering events occurring on January 31, 2020. The filing details a material amendment to the company's existing debt facility with Silicon Valley Bank (SVB).
Key Financial Metrics and Debt Structure
- Facility Size: $25.0 million term loan facility.
- Interest Rate: The greater of (i) Prime Rate + 3.00% or (ii) 7.75%.
- Upfront Costs: $0.5 million refinancing fee paid to SVB upon entry into the amendment.
- Final Payment: 6.0% of the aggregate principal amount advanced.
- Repayment Terms: Interest-only through June 30, 2022, followed by principal and interest over 18 months.
- Maturity Date: December 1, 2023 (or March 31, 2023, if specific trial requirements are not met).
Material Changes and Conditions
The Third Amendment refinances the outstanding balance under the previous loan facility and extends the maturity date. A critical condition affects the repayment schedule: if Savara does not have an ongoing Phase 3 or Phase 4 clinical trial for its Molgradex product (for autoimmune pulmonary alveolar proteinosis) with the first patient dosed by March 31, 2021, the interest-only period ends early. In that scenario, principal and interest payments would begin on April 1, 2021, over 24 months, and the final maturity date would move to March 31, 2023.
Additionally, the agreement includes an affirmative covenant requiring Savara to deliver evidence by June 30, 2021, of receiving at least $25.0 million in gross cash proceeds from the exercise of outstanding warrants or the issuance of other equity securities.
Outlook, Risks, and Warrant Amendments
In connection with the loan amendment, Savara amended outstanding warrants issued to SVB and its affiliate, Life Science Loans II, LLC. The exercise price for these warrants was revised to the lesser of the average closing price of Savara's Common Stock for the 10 trading days prior to the effective date or the closing price on the day prior to the effective date.
Key risks include the company's ability to meet the clinical trial milestone by March 31, 2021, to maintain favorable repayment terms, and the requirement to raise $25.0 million in equity proceeds by June 30, 2021, to satisfy loan covenants.
Investor Verification Checklist
- Verify the status of the Molgradex Phase 3 or Phase 4 clinical trial and whether the first patient has been dosed by March 31, 2021.
- Monitor Savara's capital raising activities to ensure the $25.0 million equity proceeds covenant is met by June 30, 2021.
- Review the specific terms of the warrant amendments (Exhibits 4.1-4.6) to understand the dilution impact on existing shareholders.
- Assess the company's liquidity position given the 6.0% final payment obligation and the potential for accelerated principal repayment if trial milestones are missed.